BioSpace News Archive

XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2, the virus that causes COVID-19. The Company discovered these antibodies through a collaboration with BioBridge Global (parent organization of the South Texas Blood & Tissue Center and QualTex Laboratories, one of the largest independent testing laboratories in the United States). For the c

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2020 on August 20, 2020, before the U.S. financial markets open. Entera’s management will host a conference call on Thursday, August 20, 2020 at 8:30 a.m. EDT to discuss the results for the quarter. A question-and-answer session will follow En

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services (BRS) for its CRISPR genome-edited trait C3007 in canola plant lines developed for increased oil content. Yield10’s submission along with the USDA-APHIS BRS response is posted on the USDA’s website . In June 2020, Yield10 submitted an “Am I regulated?” let

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”) announced today that all proposals related to the proposed merger between DelMar and Adgero were approved by DelMar’s stockholders at a special meeting held on August 14 , 2020. The holders of a majority of the outstanding shares of common stock of Adgero have also

Swift Biosciences, Inc., a leader in the commercialization of DNA and RNA Library Preparation Kits recently launched a new ACE2 Swift Normalase® Amplicon Panel (SNAP) to further research on the main functional receptor for viral entry of Coronavirus. With global numbers of COVID-19 cases increasing, Swift remains committed to prov

Phase 1/2a trial of Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19 is on track for enrollment

CytoSorbents Corporation has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure.

World’s First Fully Disposable Surgical Robot Achieved all Endpoints with No Intraoperative Adverse Events Remotely Performed Procedures have the Potential to Reduce Radiation Exposure, Physical Strain and Cross Contamination to Both the Patients and the Surgical Staff

Achieves analytical performance for detecting active 3C-protease in a rapid visual format Initiates multicenter clinical trial at Assuta Ashdod Hospital and Tel Aviv University in Israel Technology opens potential for self-administered tests at home, school, work and airports

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced it will host a conference call and webcast to provide a business update on Monday, August 31, 2020 at 4:30 p.m. EDT.